Scribe Therapeutics Inc. SCTX
12.07 USD -1.15 (-8.70%)
Regular-session close
12.00 -0.07 -0.58%
After hours · Nov 20, 4:00 PM ET
12.00 Day range 13.40
12.00 52-week range 39.60
- YTD
- -36.37%
- 1 year
- -36.37%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Scribe Therapeutics (NASDAQ:SCTX) with a Buy and maintains $60 price target.
benzinga.com Scribe Therapeutics Reports Updated Preclinical Data From STX-1150 And STX-1200 Programs At AHA Scientific Sessions 2026 Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol…
globenewswire.com Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026 Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol…benzinga.com Scribe Therapeutics Q3 EPS $(0.68) Beats $(2.06) Estimate, Sales $1.600M Miss $3.113M Estimate Scribe Therapeutics (NASDAQ:SCTX) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(2.06) by 66.99 percent. The company reported quarterly sales of $1.600…
benzinga.com Scribe Therapeutics To Present Data In American Heart Association’s Scientific Sessions On Its Three Clinical Programs Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend…
